{"transactions":[{"id":4634954,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":74154,"kind":"person","name":"Kelly Thomas Patrick","position":1,"cik":"0001410514","reported_name":"Kelly Thomas Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2026-10-01T17:20:20.000Z","date":"2026-09-30","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":37.316,"value":559740.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001193125-26-410001","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410514/000119312526410001/ownership.xml","form_type":"4"}},{"id":4635396,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-10-01T17:19:28.000Z","date":"2026-09-30","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":37.38,"value":1121400.0,"ownership":{"direct":true},"balance_after":49923,"source":{"system":"sec-edgar","filing":"0001193125-26-409999","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526409999/ownership.xml","form_type":"4"}},{"id":3921,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T00:26:18.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":false,"shares":5144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":8.15,"expiration_date":"2026-09-26","underlying":"Common Shares","underlying_shares":5144},"source":{"system":"sec-edgar","filing":"0001193125-26-382412","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526382412/ownership.xml","form_type":"4"}},{"id":3920,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-04T00:26:18.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":true,"shares":5144,"price":8.15,"value":41923.6,"ownership":{"direct":true},"balance_after":31373,"source":{"system":"sec-edgar","filing":"0001193125-26-382412","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526382412/ownership.xml","form_type":"4"}},{"id":672115,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-09-01T01:59:36.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":700,"price":60.9766,"value":42683.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $60.81 to $61.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares beneficially owned following the reported transactions reflects an upward adjustment of one share from the reporting person's previous Form 4 filed on March 13, 2026, based on updated tax withholding calculations for the transactions described on the previously filed Form 4."}],"balance_after":2,"source":{"system":"sec-edgar","filing":"0001193125-26-377309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526377309/ownership.xml","form_type":"4"}},{"id":672114,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-09-01T01:59:36.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":6368,"price":60.1673,"value":383145.3664,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $59.79 to $60.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":702,"source":{"system":"sec-edgar","filing":"0001193125-26-377309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526377309/ownership.xml","form_type":"4"}},{"id":687957,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-08-13T20:33:27.000Z","date":"2026-08-11","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":64.055,"value":640550.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $64.0517 to $64.078, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":1870,"source":{"system":"sec-edgar","filing":"0001193125-26-349351","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526349351/ownership.xml","form_type":"4"}},{"id":746005,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":40437,"kind":"person","name":"PATOU GARY","position":1,"cik":"0001283535","reported_name":"PATOU GARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-09T01:19:45.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":1322,"price":53.14,"value":70251.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 17, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025."}],"balance_after":24896,"source":{"system":"sec-edgar","filing":"0001193125-26-262672","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283535/000119312526262672/ownership.xml","form_type":"4"}},{"id":745794,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":40386,"kind":"person","name":"Cannon Gillian","position":1,"cik":"0001833910","reported_name":"Cannon Gillian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-09T01:19:23.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":1190,"price":53.14,"value":63236.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 15, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025."}],"balance_after":1455,"source":{"system":"sec-edgar","filing":"0001193125-26-262671","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526262671/ownership.xml","form_type":"4"}},{"id":751360,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":40437,"kind":"person","name":"PATOU GARY","position":1,"cik":"0001283535","reported_name":"PATOU GARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:59.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":1593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":1593,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":1593},"source":{"system":"sec-edgar","filing":"0001193125-26-256126","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1283535/000119312526256126/ownership.xml","form_type":"4"}},{"id":751359,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":40437,"kind":"person","name":"PATOU GARY","position":1,"cik":"0001283535","reported_name":"PATOU GARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-04T01:04:59.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":10507,"derivative":{"exercise_price":53.46,"expiration_date":"2036-06-02","underlying":"Common Shares","underlying_shares":10507},"source":{"system":"sec-edgar","filing":"0001193125-26-256126","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1283535/000119312526256126/ownership.xml","form_type":"4"}},{"id":751358,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":40437,"kind":"person","name":"PATOU GARY","position":1,"cik":"0001283535","reported_name":"PATOU GARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:59.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0001193125-26-256126","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1283535/000119312526256126/ownership.xml","form_type":"4"}},{"id":751357,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":40437,"kind":"person","name":"PATOU GARY","position":1,"cik":"0001283535","reported_name":"PATOU GARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:04:59.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":2645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":26218,"source":{"system":"sec-edgar","filing":"0001193125-26-256126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283535/000119312526256126/ownership.xml","form_type":"4"}},{"id":751208,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:45.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":1593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":1593,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":1593},"source":{"system":"sec-edgar","filing":"0001193125-26-256125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000119312526256125/ownership.xml","form_type":"4"}},{"id":751207,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-04T01:04:45.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":10507,"derivative":{"exercise_price":53.46,"expiration_date":"2036-06-02","underlying":"Common Shares","underlying_shares":10507},"source":{"system":"sec-edgar","filing":"0001193125-26-256125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000119312526256125/ownership.xml","form_type":"4"}},{"id":751206,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:45.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0001193125-26-256125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000119312526256125/ownership.xml","form_type":"4"}},{"id":751205,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:04:45.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":2645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":2645,"source":{"system":"sec-edgar","filing":"0001193125-26-256125","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000119312526256125/ownership.xml","form_type":"4"}},{"id":751856,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":39300,"kind":"person","name":"Gover Justin D.","position":1,"cik":"0001754129","reported_name":"Gover Justin D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:31.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":1593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":1593,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":1593},"source":{"system":"sec-edgar","filing":"0001193125-26-256124","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754129/000119312526256124/ownership.xml","form_type":"4"}},{"id":751855,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":39300,"kind":"person","name":"Gover Justin D.","position":1,"cik":"0001754129","reported_name":"Gover Justin D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-04T01:04:31.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":10507,"derivative":{"exercise_price":53.46,"expiration_date":"2036-06-02","underlying":"Common Shares","underlying_shares":10507},"source":{"system":"sec-edgar","filing":"0001193125-26-256124","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754129/000119312526256124/ownership.xml","form_type":"4"}},{"id":751854,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":39300,"kind":"person","name":"Gover Justin D.","position":1,"cik":"0001754129","reported_name":"Gover Justin D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:31.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0001193125-26-256124","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754129/000119312526256124/ownership.xml","form_type":"4"}},{"id":751853,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":39300,"kind":"person","name":"Gover Justin D.","position":1,"cik":"0001754129","reported_name":"Gover Justin D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:04:31.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":2645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":2645,"source":{"system":"sec-edgar","filing":"0001193125-26-256124","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754129/000119312526256124/ownership.xml","form_type":"4"}},{"id":750901,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":37117,"kind":"person","name":"GAROFALO ELIZABETH A.","position":1,"cik":"0001826361","reported_name":"GAROFALO ELIZABETH A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:14.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":1593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":1593,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":1593},"source":{"system":"sec-edgar","filing":"0001193125-26-256122","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526256122/ownership.xml","form_type":"4"}},{"id":750900,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":37117,"kind":"person","name":"GAROFALO ELIZABETH A.","position":1,"cik":"0001826361","reported_name":"GAROFALO ELIZABETH A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-04T01:04:14.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":10507,"derivative":{"exercise_price":53.46,"expiration_date":"2036-06-02","underlying":"Common Shares","underlying_shares":10507},"source":{"system":"sec-edgar","filing":"0001193125-26-256122","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526256122/ownership.xml","form_type":"4"}},{"id":750899,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":37117,"kind":"person","name":"GAROFALO ELIZABETH A.","position":1,"cik":"0001826361","reported_name":"GAROFALO ELIZABETH A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:14.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0001193125-26-256122","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526256122/ownership.xml","form_type":"4"}},{"id":750898,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":37117,"kind":"person","name":"GAROFALO ELIZABETH A.","position":1,"cik":"0001826361","reported_name":"GAROFALO ELIZABETH A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:04:14.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":2645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":2645,"source":{"system":"sec-edgar","filing":"0001193125-26-256122","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526256122/ownership.xml","form_type":"4"}},{"id":751710,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:00.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":1593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":1593,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":1593},"source":{"system":"sec-edgar","filing":"0001193125-26-256121","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526256121/ownership.xml","form_type":"4"}},{"id":751709,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-04T01:04:00.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":10507,"derivative":{"exercise_price":53.46,"expiration_date":"2036-06-02","underlying":"Common Shares","underlying_shares":10507},"source":{"system":"sec-edgar","filing":"0001193125-26-256121","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526256121/ownership.xml","form_type":"4"}},{"id":751708,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:00.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0001193125-26-256121","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526256121/ownership.xml","form_type":"4"}},{"id":751707,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:04:00.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1416,"price":53.41,"value":75628.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of Common Shares withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of the RSUs, and does not represent a sale."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the closing price of Common Shares on June 1, 2026 for purposes of net settlement calculations."}],"balance_after":11870,"source":{"system":"sec-edgar","filing":"0001193125-26-256121","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526256121/ownership.xml","form_type":"4"}},{"id":751706,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:04:00.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":2645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":13286,"source":{"system":"sec-edgar","filing":"0001193125-26-256121","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526256121/ownership.xml","form_type":"4"}},{"id":750897,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":40386,"kind":"person","name":"Cannon Gillian","position":1,"cik":"0001833910","reported_name":"Cannon Gillian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:03:40.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":1593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":1593,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":1593},"source":{"system":"sec-edgar","filing":"0001193125-26-256120","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526256120/ownership.xml","form_type":"4"}},{"id":750896,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":40386,"kind":"person","name":"Cannon Gillian","position":1,"cik":"0001833910","reported_name":"Cannon Gillian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-04T01:03:40.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":10507,"derivative":{"exercise_price":53.46,"expiration_date":"2036-06-02","underlying":"Common Shares","underlying_shares":10507},"source":{"system":"sec-edgar","filing":"0001193125-26-256120","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526256120/ownership.xml","form_type":"4"}},{"id":750895,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":40386,"kind":"person","name":"Cannon Gillian","position":1,"cik":"0001833910","reported_name":"Cannon Gillian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:03:40.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0001193125-26-256120","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526256120/ownership.xml","form_type":"4"}},{"id":750894,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":40386,"kind":"person","name":"Cannon Gillian","position":1,"cik":"0001833910","reported_name":"Cannon Gillian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:03:40.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":2645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":2645,"source":{"system":"sec-edgar","filing":"0001193125-26-256120","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526256120/ownership.xml","form_type":"4"}},{"id":750919,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:03:24.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":1593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":1593,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":1593},"source":{"system":"sec-edgar","filing":"0001193125-26-256118","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000119312526256118/ownership.xml","form_type":"4"}},{"id":750918,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-04T01:03:24.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":10507,"derivative":{"exercise_price":53.46,"expiration_date":"2036-06-02","underlying":"Common Shares","underlying_shares":10507},"source":{"system":"sec-edgar","filing":"0001193125-26-256118","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000119312526256118/ownership.xml","form_type":"4"}},{"id":750917,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:03:24.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0001193125-26-256118","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000119312526256118/ownership.xml","form_type":"4"}},{"id":750916,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:03:24.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1416,"price":53.41,"value":75628.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of Common Shares withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of the RSUs, and does not represent a sale."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the closing price of Common Shares on June 1, 2026 for purposes of net settlement calculations."}],"balance_after":26229,"source":{"system":"sec-edgar","filing":"0001193125-26-256118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000119312526256118/ownership.xml","form_type":"4"}},{"id":750915,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:03:24.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":2645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":27645,"source":{"system":"sec-edgar","filing":"0001193125-26-256118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000119312526256118/ownership.xml","form_type":"4"}},{"id":780808,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-14T01:40:43.000Z","date":"2026-05-12","kind":"exercise","planned":false,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.38,"expiration_date":"2026-06-01","underlying":"Common Shares","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001193125-26-222369","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526222369/ownership.xml","form_type":"4"}},{"id":780807,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-05-14T01:40:43.000Z","date":"2026-05-12","kind":"exercise","planned":false,"acquired":true,"shares":3500,"price":7.38,"value":25830.0,"ownership":{"direct":true},"balance_after":10641,"source":{"system":"sec-edgar","filing":"0001193125-26-222369","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526222369/ownership.xml","form_type":"4"}},{"id":844080,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Share Units","published_at":"2026-03-14T00:16:56.000Z","date":"2026-03-12","kind":"exercise","planned":true,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":11250,"derivative":{"underlying":"Common Shares","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001193125-26-106727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526106727/ownership.xml","form_type":"4"}},{"id":844079,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-03-14T00:16:56.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":1410,"price":55.225,"value":77867.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of RSUs granted on March 12, 2025."}],"balance_after":7069,"source":{"system":"sec-edgar","filing":"0001193125-26-106727","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526106727/ownership.xml","form_type":"4"}},{"id":844078,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-03-14T00:16:56.000Z","date":"2026-03-12","kind":"exercise","planned":true,"acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":8479,"source":{"system":"sec-edgar","filing":"0001193125-26-106727","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526106727/ownership.xml","form_type":"4"}},{"id":843544,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Restricted Share Units","published_at":"2026-03-14T00:16:26.000Z","date":"2026-03-12","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":37500,"derivative":{"underlying":"Common Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001193125-26-106724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526106724/ownership.xml","form_type":"4"}},{"id":843543,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-14T00:16:26.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":7308,"price":55.225,"value":403584.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of RSUs granted on March 12, 2025."}],"balance_after":19923,"source":{"system":"sec-edgar","filing":"0001193125-26-106724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526106724/ownership.xml","form_type":"4"}},{"id":843542,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-14T00:16:26.000Z","date":"2026-03-12","kind":"exercise","planned":true,"acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":27231,"source":{"system":"sec-edgar","filing":"0001193125-26-106724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526106724/ownership.xml","form_type":"4"}},{"id":843922,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Share Units","published_at":"2026-03-13T20:16:43.000Z","date":"2026-03-12","kind":"exercise","planned":true,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":11250,"derivative":{"underlying":"Common Shares","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001193125-26-106726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526106726/ownership.xml","form_type":"4"}},{"id":843921,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-03-13T20:16:43.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":1342,"price":55.225,"value":74111.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of RSUs granted on March 12, 2025."}],"balance_after":7301,"source":{"system":"sec-edgar","filing":"0001193125-26-106726","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526106726/ownership.xml","form_type":"4"}},{"id":843920,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-03-13T20:16:43.000Z","date":"2026-03-12","kind":"exercise","planned":true,"acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":8643,"source":{"system":"sec-edgar","filing":"0001193125-26-106726","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526106726/ownership.xml","form_type":"4"}},{"id":848990,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance Share Units","published_at":"2026-03-11T23:21:20.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001193125-26-102669","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526102669/ownership.xml","form_type":"4"}},{"id":848989,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance Share Units","published_at":"2026-03-11T23:21:20.000Z","date":"2026-03-09","kind":"grant","planned":true,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":7500,"derivative":{"underlying":"Common Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001193125-26-102669","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526102669/ownership.xml","form_type":"4"}},{"id":848988,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-03-11T23:21:20.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":2771,"price":60.108,"value":166559.268,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of PSUs granted on March 11, 2024."}],"balance_after":4729,"source":{"system":"sec-edgar","filing":"0001193125-26-102669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526102669/ownership.xml","form_type":"4"}},{"id":848987,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-03-11T23:21:20.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001193125-26-102669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526102669/ownership.xml","form_type":"4"}},{"id":848237,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Performance Share Units","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848236,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Performance Share Units","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"grant","planned":true,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"shares","element":"transactionShares","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":20000,"derivative":{"underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848235,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The shares subject to this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":9.44,"expiration_date":"2029-09-15","underlying":"Common Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848234,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The shares subject to this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":4.75,"expiration_date":"2028-03-11","underlying":"Common Shares","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848233,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The shares subject to this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":3.1,"expiration_date":"2027-10-22","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848232,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The shares subject to this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":8.4,"expiration_date":"2027-03-12","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848231,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":11269,"price":60.108,"value":677357.052,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of PSUs granted on March 11, 2024."}],"balance_after":14731,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848230,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":26000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848229,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":65000,"price":62.06,"value":4033900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848228,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":65000,"price":9.44,"value":613600.0,"ownership":{"direct":true},"balance_after":71000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848227,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":61652,"price":60.08,"value":3704052.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $59.75 to $60.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848226,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":43348,"price":59.26,"value":2568802.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $58.745 to $59.735, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":72652,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848225,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":105000,"price":4.75,"value":498750.0,"ownership":{"direct":true},"balance_after":111000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848224,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":2449,"price":61.26,"value":150025.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $61.055 to $61.555, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848223,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":10072,"price":60.47,"value":609053.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $60.05 to $61.035, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":8449,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848222,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":12479,"price":59.5,"value":742500.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $59.03 to $60.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":18521,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848221,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":3.1,"value":77500.0,"ownership":{"direct":true},"balance_after":31000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848220,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":21515,"price":60.49,"value":1301442.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $60.16 to $61.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848219,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":31694,"price":59.88,"value":1897836.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $59.16 to $60.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":27515,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848218,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":21791,"price":58.81,"value":1281528.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $58.16 to $59.1425, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":59209,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848217,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":75000,"price":8.4,"value":630000.0,"ownership":{"direct":true},"balance_after":81000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848690,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance Share Units","published_at":"2026-03-11T19:20:53.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001193125-26-102667","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526102667/ownership.xml","form_type":"4"}},{"id":848689,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance Share Units","published_at":"2026-03-11T19:20:53.000Z","date":"2026-03-09","kind":"grant","planned":true,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":7500,"derivative":{"underlying":"Common Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001193125-26-102667","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526102667/ownership.xml","form_type":"4"}},{"id":848688,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-03-11T19:20:53.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":2607,"price":60.108,"value":156701.556,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of PSUs granted on March 11, 2024."}],"balance_after":4893,"source":{"system":"sec-edgar","filing":"0001193125-26-102667","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526102667/ownership.xml","form_type":"4"}},{"id":848687,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-03-11T19:20:53.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001193125-26-102667","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526102667/ownership.xml","form_type":"4"}},{"id":942295,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Share Units","published_at":"2026-01-09T23:54:57.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."}],"balance_after":20000,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-009238","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526009238/ownership.xml","form_type":"4"}},{"id":942294,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-01-09T23:54:57.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":100000,"derivative":{"exercise_price":42.15,"expiration_date":"2036-01-08","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-009238","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526009238/ownership.xml","form_type":"4"}},{"id":941835,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":38545,"kind":"person","name":"Cline Darren S","position":1,"cik":"0001633639","reported_name":"Cline Darren S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Share Units","published_at":"2026-01-09T23:53:13.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."}],"balance_after":20000,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-009235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526009235/ownership.xml","form_type":"4"}},{"id":941834,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":38545,"kind":"person","name":"Cline Darren S","position":1,"cik":"0001633639","reported_name":"Cline Darren S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-01-09T23:53:13.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":40000,"derivative":{"exercise_price":42.15,"expiration_date":"2036-01-08","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001193125-26-009235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526009235/ownership.xml","form_type":"4"}},{"id":941833,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Restricted Share Units","published_at":"2026-01-09T23:51:00.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."}],"balance_after":65000,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001193125-26-009230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526009230/ownership.xml","form_type":"4"}},{"id":941832,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Share Option (Right to Buy)","published_at":"2026-01-09T23:51:00.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":350000,"derivative":{"exercise_price":42.15,"expiration_date":"2036-01-08","underlying":"Common Shares","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001193125-26-009230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526009230/ownership.xml","form_type":"4"}},{"id":942141,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Share Units","published_at":"2026-01-09T18:52:14.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."}],"balance_after":15000,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-26-009232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526009232/ownership.xml","form_type":"4"}},{"id":942140,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60986,"kind":"person","name":"DiFabio Andrea","position":1,"cik":"0001692506","reported_name":"DiFabio Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-01-09T18:52:14.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":80000,"derivative":{"exercise_price":42.15,"expiration_date":"2036-01-08","underlying":"Common Shares","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001193125-26-009232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692506/000119312526009232/ownership.xml","form_type":"4"}},{"id":954889,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-02T23:49:48.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.49,"expiration_date":"2026-03-10","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001193125-26-001172","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526001172/ownership.xml","form_type":"4"}},{"id":954888,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-01-02T23:49:48.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":2062,"price":44.93,"value":92645.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $44.91 to $45.125, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001193125-26-001172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526001172/ownership.xml","form_type":"4"}},{"id":954887,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-01-02T23:49:48.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":37938,"price":44.4,"value":1684447.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $43.91 to $44.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":8062,"source":{"system":"sec-edgar","filing":"0001193125-26-001172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526001172/ownership.xml","form_type":"4"}},{"id":954886,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-01-02T23:49:48.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":7.49,"value":299600.0,"ownership":{"direct":true},"balance_after":46000,"source":{"system":"sec-edgar","filing":"0001193125-26-001172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526001172/ownership.xml","form_type":"4"}},{"id":975570,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-12-10T00:40:08.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":2010,"price":46.32,"value":93103.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.02 to $46.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001193125-25-313147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525313147/ownership.xml","form_type":"4"}},{"id":975569,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-12-10T00:40:08.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":8820,"price":45.59,"value":402103.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $45.02 to $46.013, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":8010,"source":{"system":"sec-edgar","filing":"0001193125-25-313147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525313147/ownership.xml","form_type":"4"}},{"id":975568,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-12-10T00:40:08.000Z","date":"2025-12-05","kind":"sale","planned":true,"acquired":false,"shares":14375,"price":45.03,"value":647306.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $45.00 to $45.135, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":16830,"source":{"system":"sec-edgar","filing":"0001193125-25-313147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525313147/ownership.xml","form_type":"4"}},{"id":981095,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-12-04T01:20:44.000Z","date":"2025-11-28","kind":"sale","planned":true,"acquired":false,"shares":97,"price":45.01,"value":4365.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."}],"balance_after":31205,"source":{"system":"sec-edgar","filing":"0001193125-25-307211","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525307211/ownership.xml","form_type":"4"}},{"id":1016676,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":74154,"kind":"person","name":"Kelly Thomas Patrick","position":1,"cik":"0001410514","reported_name":"Kelly Thomas Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2025-10-17T18:43:47.000Z","date":"2025-10-15","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on October 15, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on October 15, 2026."}],"balance_after":30000,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-25-242700","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410514/000119312525242700/ownership.xml","form_type":"4"}},{"id":1016675,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":74154,"kind":"person","name":"Kelly Thomas Patrick","position":1,"cik":"0001410514","reported_name":"Kelly Thomas Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2025-10-17T18:43:47.000Z","date":"2025-10-15","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on October 15, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":225000,"derivative":{"exercise_price":41.9,"expiration_date":"2035-10-14","underlying":"Common Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001193125-25-242700","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410514/000119312525242700/ownership.xml","form_type":"4"}},{"id":1029066,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO & INTERIM CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-01T23:17:11.000Z","date":"2025-10-01","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.69,"expiration_date":"2025-12-17","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-227202","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525227202/ownership.xml","form_type":"4"}},{"id":1029065,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO & INTERIM CFO"}}],"security":"Common Shares","published_at":"2025-10-01T23:17:11.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":40.16,"value":1004000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.495, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":31302,"source":{"system":"sec-edgar","filing":"0001193125-25-227202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525227202/ownership.xml","form_type":"4"}},{"id":1029064,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO & INTERIM CFO"}}],"security":"Common Shares","published_at":"2025-10-01T23:17:11.000Z","date":"2025-10-01","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":7.69,"value":192250.0,"ownership":{"direct":true},"balance_after":56302,"source":{"system":"sec-edgar","filing":"0001193125-25-227202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525227202/ownership.xml","form_type":"4"}}],"next_cursor":"2025-10-01T23:17:11.000000Z,1029064"}